FORT MYERS, Fla. - NeoGenomics, Inc. (NASDAQ: NEO), a provider of cancer testing services with annual revenue of $672 million and healthy liquidity metrics, has introduced a new diagnostic assay, ...

Qiagen has announced the US Food and Drug Administration (FDA) approval of its therascreen KRAS RGQ PCR kit (therascreen KRAS kit) as a companion diagnostic test to Mirati Therapeutic’s drug Krazati ...

—A team of researchers in Tokyo recently took on the challenge of attempting to determine whether comprehensive genomic profiling has clinical utility in a large cohort of patients with non-small cell ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Please provide your email address to receive an email when new articles are posted on . NCCN recommends osimertinib plus chemotherapy or lazertinib plus amivantamab-vmjw as first-line options for EGFR ...

“It's My Wish, We Need This Program”: Qualitative Reflections From People With High-Grade Brain Cancer Consenting to Postmortem Brain Donation Targeted therapy has transformed treatment of non–small ...